Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirilumab + Nivolumab +/- Ipilimumab in Advanced Solid Tumors
NCT03203876Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of lirilumab in solid tumor (advanced stage) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of dose-limiting toxicity at 2 years, Incidence of adverse events at 2 years and 4 more. Started Jul 2017; status: completed.
02
Drugs
lirilumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03203876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203876.